Medical Press Release - Page 2 of 12 - Medika Life : Keeping you informed

An international team of researchers reports in the New England Journal of Medicine dramatically transforming aPAP treatment by helping develop a drug that patients can inhale once a day so their body will clear out the pulmonary waste.

Uqora Develops the First Non-Antibiotic Treatment Option for UTIs

Medika Life - September 29, 2020

The new drug program aims to decrease the amount of UTIs that would otherwise require antibiotic intervention.

Private Practice: Solution Mode to Survival Mode

Medika Life - September 21, 2020

A true glimpse into the process of transitioning a practice and how it can be a great solution to the issues facing private practices. Many are struggling,

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Medika Life - August 12, 2020

SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

AI-Driven Model Supports Safer and More Precise Blood Sugar Management After Heart Surgery

Corundum Convergence Institute Launches to Catalyze Funding for Research and Innovation in Neuroscience and Systems Biology

StuffThatWorks and The Marfan Foundation to Engage in Pilot Program

Intellihealth Chief Medical Officer, Dr. Leon Igel, Honored as American Diabetes Association Greater New York Research Dinner Medical Honoree of the Year

LATEST

TRENDING

Medika’s Call for Food Aid for Starving Filipino Children

Lover, the App That Helps Women Reach Orgasm

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

The 50 Most Influential Leaders in Pharmacy 2022 Awards

The Nation’s Only Virtual At-Home Detox Programs from Workit Health Expands

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

FINN Partners Brings Aboard the Pharmacy Podcast Network

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

South University Announces New MSPA Program at West Palm Beach Campus

Parnell Pharmaceuticals Announces Nomovid™ Antiviral Nasal Spray

EDITORS CHOICE

Doctors Find Drug for Lethal Lung Disease After Decades of Trying

Uqora Develops the First Non-Antibiotic Treatment Option for UTIs

Private Practice: Solution Mode to Survival Mode

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories